Loading
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Previous close
$1.27
−$0.14 · -9.93%
Pre-market
$1.20
−$0.07 · -5.51%
Oct 8, 8:55 AM ET
Regular session · ET · Market data may be delayed.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Day range
Current $1.27
52-week range
Current $1.27
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
59
Mixed
Risk
66
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Day range
Current $1.27
52-week range
Current $1.27
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | 65.3M USD | 48.82M USD | 40.7M USD |
| Cost of goods sold | — | 368K USD | — | — | — |
| Gross profit | — | −368K USD | 65.3M USD | 48.82M USD | 40.7M USD |
| Research and development | 122K USD | 3.92M USD | 16.56M USD | 52.45M USD | 85.64M USD |
| Selling, general, and administrative | 12.15M USD | 13.53M USD | 23.3M USD | 33.13M USD | 30.54M USD |
| Operating expenses | 12.27M USD | 17.09M USD | 50.76M USD | 85.58M USD | 116.18M USD |
| Interest income | 267K USD | 1.03M USD | 3.28M USD | 3.35M USD | 284K USD |
| Depreciation and amortization | — | 368K USD | 383K USD | 386K USD | 326K USD |
| Operating income | −12.27M USD | −17.46M USD | 14.54M USD | −36.76M USD | −75.48M USD |
| Net income | −71.15M USD | −15.95M USD | 17.78M USD | −31.84M USD | −54.45M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Nov 16, 2023 | $1.75Special | Nov 17, 2023 | Dec 6, 2023 |
Ex-dividend Nov 16, 2023
$1.75
Special
Record Nov 17, 2023 · Payment Dec 6, 2023
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
